Chiome Bioscience (4583)
|7,719 million yen|
An innovative biotech company with core competence in antibody generation. Focus on the development of robust and more effective therapeutics and diagnostics leveraging our novel antibody generation platforms.
ADLib® system represents “One-stop-order platform for antibody drug discovery”
The ADLib® system offers a platform library with unique array space that adds seamless Affinity maturation function. It is a one stop order drug discovery and research tool that can complete all the steps necessary for antibody drug discovery such as selection, full-length IgG expression, humanization, and affinity maturation on 1 platform.
Antibody selection with ADLib® – “Robust and simple method”
TribodyTM :Multi-specific antibody format
Tribody™ enables creation of unique antibody that differentiates from conventional antibody, by building multi-binding sites that bind to different antigen or epitope. This unique technology overcomes the key shortcomings of conventional mono- as well as of currently developed bi-specific antibody formats.
CBA-1205, a therapeutic antibody for cancer that is currently in Phase I clinical trials, is a first-in-class antibody that targets DLK-1, while CBA-1535, a multivalent antibody that simultaneously targets tumour antigens and T cells, is the world’s first multivalent antibody in the Tribody format to undergo clinical trials. We expect to generate significant revenue from 2024 onwards by out-licensing both pipelines to pharmaceutical companies. In addition, we will create the third clinical development product following these by 2023.
Top executive speaks to investors